The urokinase receptor

Fibrinolysis and Proteolysis

Volumn 8, Issue SUPPL. 1, 1994, Pages 172-181

  Vassalli, J D ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

CONFERENCE PAPER; FIBRINOLYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0027981123     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-9499(94)90715-3     Document Type: Article

References (94)

1. The plasminogen activator/plasmin system
2. Plasminogen in the chick embryo. Transport and biosynthesis
3. Local synthesis of plasminogen by the seminiferous tubules of the testis
4. Production and secretion of plasminogen in cultured rat brain microglia
5. Retinoic acid enhances the secretion of plasminogen from cultured rat microglia
6. Extracellular proteolysis in the adult murine brain
7. Meiotic maturation of mouse oocytes triggers the translation and polyadenylation of dormant tissue-type plasminogen activator mRNA
8. A sensitive ELISA for human tissue-type plasminogen activator applicable to the study of acute release from cultured human endothelial cells
9. Mouse ovarian granulosa cells produce urokinase-type plasminogen activator, whereas the corresponding rat cells produce tissuetype plasminogen activator
10. The chicken urokinase-type plasminogen activator gene
11. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain
12. Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator
13. Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator
14. Onechain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity
15. Sites of synthesis of urokinase and tissue-type plasminogen activators in the marine kidney
16. Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface
17. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system
18. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases
19. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor
20. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells
21. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
22. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
23. Proteolytic balance and capillary morphogenesis
24. Transforming growth factor-beta I modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro
25. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene
26. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator
27. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase
28. Differentiation-enhanced binding of the aminoterminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes
29. The receptor-binding sequence of urokinase. A biological function for the growthfactor module of proteases
30. Characterization of the cellular binding site for the urokinase-type plasminogen activator
31. A 55,000–60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumour cell lines and partial purification
32. The human receptor for urokinase plasminogen activator
33. Cellular receptor for urokinase plasminogen activator. Carboxylterminal processing and membrane anchoring by glycosylphosphatidylinositol
34. The receptor for urokinasetype plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria
35. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
36. The ligand-binding domain of the cell surface receptor for urokinasetype plasminogen activator
37. The N-terminal domain of human urokinase receptor contains two distinct regions critical for ligand recognition
38. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract
39. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator
40. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligandbinding domain
41. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer
42. Interaction of urokinase-type plasminogen activator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein
43. Urokinase receptors in human monocytes
44. The receptor for urokinasetype plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils
45. Identification and characterization of urokinase receptors in natural killer cells and T-cell-derived lymphokine activated killer cells
46. Urokinase receptor: An activation antigen in human T lymphocytes
47. Interaction of singlechain urokinase-type plasminogen activator with human endothelial cells
48. Urokinase binding and receptor identification in cultured endothelial cells
49. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens
50. Alveolar macrophage urokinase receptors localize enzyme activity to the cell surface
51. Modulation of activities and RNA level of the components of the plasminogen activation system during fusion of human myogenic satellite cells in vitro
52. Role of specific membrane receptors in urokinase-dependent migration of human keratinocytes
53. Interaction of urokinase A chain with the receptor of human keratinocytes stimulates release of urokinase-like plasminogen activator
54. Characterization of urokinase receptor expression by human placental trophoblasts
55. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator
56. Bovine urokinase-type plasminogen activator and its receptor: Cloning and induction by retinoic acid
57. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
58. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer
59. Human urokinase receptor concentration in malignant and benign breast tumours by in vitro quantitative autoradiography: Comparison with urokinase levels
60. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers
61. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue
62. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumour progression
63. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells
64. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate
65. N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand.
66. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
67. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin
68. Ultrastructural localization of plasma membrane-associated urokinase- type plasminogen activator at focal contacts
69. Upregulation of urokinase receptor expression on migrating endothelial cells
70. Autocrine saturation of pro-urokinase receptors on human A431 cells
71. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
72. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors
73. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1
74. 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes
75. Plasminogen and plasminogen activator assembly on the human endothelial cell
76. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes
77. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cellassociated and isolated receptor
78. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor
79. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity
80. Requirement for receptorbound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-f3
81. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
82. Release of basic fibroblast growth factorheparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity
83. In vivo paracrine interaction between urokinase and its receptor: Effect on tumour cell invasion
84. Invasion of connective tissue by human carcinoma cell lines: Requirement for urokinase, urokinase receptor, and interstitial collagenase
85. Prevention of metastasis by inhibition of the urokinase receptor
86. Urokinaseurokinase receptor interaction: Non-mitogenic signal transduction in human epidermal cells
87. Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells
88. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells
89. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines
90. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors
91. The urokinase receptor is required for human monocyte chemotaxis in vitro
92. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase
93. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases
94. Physiological consequences of loss of plasminogen activator gene function in mice